X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

CANCER AND METASTASIS REVIEWS

期刊標題檢索 CANCER METAST R 最新評論: You can also submit your own articles (2022-03-20)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[CANCER AND METASTASIS REVIEWS]您好,您是該頁面的第 24780 位訪客。

期刊簡介
期刊名稱CANCER AND METASTASIS REVIEWS CANCER AND METASTASIS REVIEWS
LetPub Score
7.8
50 ratings
Rate

Reputation
8.8

Influence
6.7

Speed
9.1

期刊簡稱CANCER METAST REV
ISSN0167-7659
E-ISSN1573-7233
h-index134
CiteScore
CiteScoreSJRSNIPCiteScore Rank
17.002.8661.934
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q129 / 404
Category: Medicine
Subcategory: Cancer Research
Q122 / 230

自引率 (2023-2024)1.30%自引率趨勢
掲載範囲
Contemporary biomedical research is on the threshold of an era in which physiological and pathological processes can be analyzed in increasingly precise and mechanistic terms. The transformation of biology from a largely descriptive, phenomenological discipline to one in which the regulatory principles can be understood and manipulated with predictability brings a new dimension to the study of cancer and the search for effective therapeutic modalities for this disease. Cancer and Metastasis Reviews provides a forum for critical review and discussion of these challenging developments.

Each issue of Cancer and Metastasis Reviews is devoted to a particular theme or topic and will contain from five to seven different contributions. In addition, an introductory preface is included from an individual who is distinguished in the field to be covered. The topics and contributors are chosen by the Editor-in-Chief after consultation with various members of the Editorial Advisory Board. Special emphasis is placed on subjects which are of relevance to the molecular and cellular biology of cancer metastasis and tumor progression, as well as to the treatment of metastatic disease. Occasional issues will be devoted to an in-depth clinical and biological analysis of a particular type of cancer.

A major function of the journal is to review some of the more important and interesting recent developments in the biology and treatment of malignant disease, as well as to highlight new and promising directions, be they technological or conceptual. Contributors are encouraged to review their personal work and be speculative.
官方網站https://www.springer.com/10555
在線稿件提交https://www.editorialmanager.com/canc
開放訪問No
出版商Springer US
主題領域医学
出版國/地區UNITED STATES
發行頻率四半期刊行
創刊年1982
每年文章數71每年文章數趨勢
黃金OA百分比43.10%
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
ONCOLOGYSCIEQ137/322
索引 (SCI or SCIE)Science Citation Index
Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0167-7659%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Slow, 6-12 Week(s)
競爭力 *來自作者的數據: Difficult
參考鏈接
相關期刊 【CANCER AND METASTASIS REVIEWS】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    CA-A CANCER JOURNAL FOR CLINICIANSH-index: 144

    CiteScore: 873.20
    Nature Reviews Clinical OncologyH-index: 127

    CiteScore: 99.40
    NATURE REVIEWS CANCERH-index: 396

    CiteScore: 111.90
    ANNALS OF ONCOLOGYH-index: 210

    CiteScore: 63.90
    CANCER CELLH-index: 295

    CiteScore: 55.20
    JOURNAL OF CLINICAL ONCOLOGYH-index: 494

    CiteScore: 41.20
    LANCET ONCOLOGYH-index: 274

    CiteScore: 62.10
    CANCER RESEARCHH-index: 411

    CiteScore: 16.10
    SEMINARS IN CANCER BIOLOGYH-index: 134

    CiteScore: 26.80
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCHH-index: 67

    CiteScore: 18.20
    學科內最受檢索的期刊 頁面查看次數
    CANCER LETTERS330960
    CANCER RESEARCH312133
    BMC CANCER245498
    Asian Pacific Journal of Cancer Prevention219198
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH198015
    INTERNATIONAL JOURNAL OF CANCER191629
    CLINICAL CANCER RESEARCH181666
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY176405
    ONCOLOGY REPORTS175031
    CA-A CANCER JOURNAL FOR CLINICIANS163632
  •  

    CANCER AND METASTASIS REVIEWS CANCER AND METASTASIS REVIEWS
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [CANCER AND METASTASIS REVIEWS] 的評論撰寫評論
作者: 子薇姑娘


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-03-20 11:31:42 評論於
You can also submit your own articles
(0) 讚! | 子薇姑娘

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 18:45:33 評論於
Suggested to complete the main results section, you can start writing the article, or you can start thinking about the article after obtaining the main phenotype data or completing the design of the study, and write it while doing it
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 17:53:45 評論於
Generally includes sections such as title, abstract, introduction, methods, results, conclusion, tables (including table titles and notes), acknowledgments, conflicts of interest, and references
(0) 讚! | 维尔娜菲茨杰拉德

作者: 八坂篷蔚


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-27 18:42:01 評論於
What are the main components of a research article?
(0) 讚! | 八坂篷蔚

作者: 平原文波


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-26 21:23:27 評論於
At what stage of the experiment is it appropriate to start writing the article?
(0) 讚! | 平原文波

作者: 虚徒熙晨


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-10-22 20:42:35 評論於
Is it a commissioned review?
(0) 讚! | 虚徒熙晨

作者: Quinton


領域: 医学
審稿時間: 3.0 month(s)
結果: 拒稿


撰寫評論

2019-01-17 17:57:29 評論於
The impact factor of this journal is too unstable, a little roller coasterfeel..
(0) 讚! | Quinton

作者: Herman Poe


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2015-06-19 10:53:22 評論於
Review Speed: 2.0 Experience Sharing: It is difficult, but worth trying, especially for those who have been working in tumor and metastasis research for a long time
(0) 讚! | Herman Poe

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [CANCER AND METASTASIS REVIEWS] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*